Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Study Indicates That Relora® Significantly Reduces Stress, Anxiety and Sleep Latency
Findings presented at the WorldNutra Conference indicate in randomized, placebo-controlled, parallel-group, clinical trial of 40 healthy, overweight, physically active, 25-50 year old women , that Spielberger Trait Total and Anxiety Index scores improved significantly and Relora group had twice as much average reduction in sleep latency as the placebo group.
- Study Indicates That Relora® Significantly Reduces Stress, Anxiety and Sleep Latency
Findings presented at the WorldNutra Conference indicate in randomized, placebo-controlled, parallel-group, clinical trial of 40 healthy, overweight, physically active, 25-50 year old women , that Spielberger Trait Total and Anxiety Index scores improved significantly and Relora group had twice as much average reduction in sleep latency as the placebo group.
- Dietary Fat Intake Linked to Dry Eye Syndrome in Women
Study, published in the October 2005 issue of the American Journal of Clinical Nutrition indicates that women with the highest levels of omega 3 in their diets reduced their risk of dry eye syndrome by 20 percent compared to women with the lowest levels of this fat in their diet and that a dietary ratio of omega 6 to omega 3 greater than 15:1 was associated with a 2.5-fold increased risk of dry eye syndrome in women.
- Dietary Fat Intake Linked to Dry Eye Syndrome in Women
Study, published in the October 2005 issue of the American Journal of Clinical Nutrition indicates that women with the highest levels of omega 3 in their diets reduced their risk of dry eye syndrome by 20 percent compared to women with the lowest levels of this fat in their diet and that a dietary ratio of omega 6 to omega 3 greater than 15:1 was associated with a 2.5-fold increased risk of dry eye syndrome in women.
- Dietary Fat Intake Linked to Dry Eye Syndrome in Women
Study, published in the October 2005 issue of the American Journal of Clinical Nutrition indicates that women with the highest levels of omega 3 in their diets reduced their risk of dry eye syndrome by 20 percent compared to women with the lowest levels of this fat in their diet and that a dietary ratio of omega 6 to omega 3 greater than 15:1 was associated with a 2.5-fold increased risk of dry eye syndrome in women.
- Dietary Fat Intake Linked to Dry Eye Syndrome in Women
Study, published in the October 2005 issue of the American Journal of Clinical Nutrition indicates that women with the highest levels of omega 3 in their diets reduced their risk of dry eye syndrome by 20 percent compared to women with the lowest levels of this fat in their diet and that a dietary ratio of omega 6 to omega 3 greater than 15:1 was associated with a 2.5-fold increased risk of dry eye syndrome in women.
- Dietary Fat Intake Linked to Dry Eye Syndrome in Women
Study, published in the October 2005 issue of the American Journal of Clinical Nutrition indicates that women with the highest levels of omega 3 in their diets reduced their risk of dry eye syndrome by 20 percent compared to women with the lowest levels of this fat in their diet and that a dietary ratio of omega 6 to omega 3 greater than 15:1 was associated with a 2.5-fold increased risk of dry eye syndrome in women.
- Zila Cites Second Study Linking Ester-E(R) To Healthy Cardiovascular Function
In this animal study, Ester-E(R) significantly reduced LDL-C (so-called bad cholesterol), triglycerides, and plaque formation, while regular vitamin E had no significant effect.
- Zila Cites Second Study Linking Ester-E(R) To Healthy Cardiovascular Function
In this animal study, Ester-E(R) significantly reduced LDL-C (so-called bad cholesterol), triglycerides, and plaque formation, while regular vitamin E had no significant effect.
- Zila Cites Second Study Linking Ester-E(R) To Healthy Cardiovascular Function
In this animal study, Ester-E(R) significantly reduced LDL-C (so-called bad cholesterol), triglycerides, and plaque formation, while regular vitamin E had no significant effect.
- Zila Cites Second Study Linking Ester-E(R) To Healthy Cardiovascular Function
In this animal study, Ester-E(R) significantly reduced LDL-C (so-called bad cholesterol), triglycerides, and plaque formation, while regular vitamin E had no significant effect.
- Zila Cites Second Study Linking Ester-E(R) To Healthy Cardiovascular Function
In this animal study, Ester-E(R) significantly reduced LDL-C (so-called bad cholesterol), triglycerides, and plaque formation, while regular vitamin E had no significant effect.
- New Study Published in Leading Toxicology Journal Concludes Chromax(R) Chromium Picolinate is Safe
Study, to be published in an upcoming issue of the Journal of Mutation Research, Genetic Toxicology and Environmental Mutagenesis, conducted by BioReliance Corporation and monitored by ENVIRON Health Sciences, concludes that Chromax(R) chromium picolinate does not produce chromosomal aberrations in Chinese Hamster Ovary (CHO) cells.
- New Study Published in Leading Toxicology Journal Concludes Chromax(R) Chromium Picolinate is Safe
Study, to be published in an upcoming issue of the Journal of Mutation Research, Genetic Toxicology and Environmental Mutagenesis, conducted by BioReliance Corporation and monitored by ENVIRON Health Sciences, concludes that Chromax(R) chromium picolinate does not produce chromosomal aberrations in Chinese Hamster Ovary (CHO) cells.
- New Study Published in Leading Toxicology Journal Concludes Chromax(R) Chromium Picolinate is Safe
Study, to be published in an upcoming issue of the Journal of Mutation Research, Genetic Toxicology and Environmental Mutagenesis, conducted by BioReliance Corporation and monitored by ENVIRON Health Sciences, concludes that Chromax(R) chromium picolinate does not produce chromosomal aberrations in Chinese Hamster Ovary (CHO) cells.
- New Study Published in Leading Toxicology Journal Concludes Chromax(R) Chromium Picolinate is Safe
Study, to be published in an upcoming issue of the Journal of Mutation Research, Genetic Toxicology and Environmental Mutagenesis, conducted by BioReliance Corporation and monitored by ENVIRON Health Sciences, concludes that Chromax(R) chromium picolinate does not produce chromosomal aberrations in Chinese Hamster Ovary (CHO) cells.
- Carotech Announces New Study Linking Tocomin® to Protection Against Stroke-Induced Neurodegeneration
NIH-funded study conducted at the Ohio State University Medical Center, published in the October issue of the American Heart Association’s journal STROKE, indicates that rats supplemented with Tocomin® showed more protection against stroke-induced injury compared to unsupplemented controls.
- Carotech Announces New Study Linking Tocomin® to Protection Against Stroke-Induced Neurodegeneration
NIH-funded study conducted at the Ohio State University Medical Center, published in the October issue of the American Heart Association’s journal STROKE, indicates that rats supplemented with Tocomin® showed more protection against stroke-induced injury compared to unsupplemented controls.
- Carotech Announces New Study Linking Tocomin® to Protection Against Stroke-Induced Neurodegeneration
NIH-funded study conducted at the Ohio State University Medical Center, published in the October issue of the American Heart Association’s journal STROKE, indicates that rats supplemented with Tocomin® showed more protection against stroke-induced injury compared to unsupplemented controls.
- Carotech Announces New Study Linking Tocomin® to Protection Against Stroke-Induced Neurodegeneration
NIH-funded study conducted at the Ohio State University Medical Center, published in the October issue of the American Heart Association’s journal STROKE, indicates that rats supplemented with Tocomin® showed more protection against stroke-induced injury compared to unsupplemented controls.
- Carotech Announces New Study Linking Tocomin® to Protection Against Stroke-Induced Neurodegeneration
NIH-funded study conducted at the Ohio State University Medical Center, published in the October issue of the American Heart Association’s journal STROKE, indicates that rats supplemented with Tocomin® showed more protection against stroke-induced injury compared to unsupplemented controls.
- Carotech Announces New Study Linking Tocomin® to Protection Against Stroke-Induced Neurodegeneration
NIH-funded study conducted at the Ohio State University Medical Center, published in the October issue of the American Heart Association’s journal STROKE, indicates that rats supplemented with Tocomin® showed more protection against stroke-induced injury compared to unsupplemented controls.
- Medical Journal Publishes Trial Showing Study Results of COLD-fX(R)
The Canadian Medical Association Journal will publish results of double-blind, placebo-controlled study on COLD-fX(R) for prevention and relief of upper respiratory infections; results indicate that the number of upper respiratory infections in each subject was significantly reduced by 25%, recurrent infections were reduced by 56%, and treatment also had a significant effect in reducing the total symptom score and the duration of infections.
- Medical Journal Publishes Trial Showing Study Results of COLD-fX(R)
The Canadian Medical Association Journal will publish results of double-blind, placebo-controlled study on COLD-fX(R) for prevention and relief of upper respiratory infections; results indicate that the number of upper respiratory infections in each subject was significantly reduced by 25%, recurrent infections were reduced by 56%, and treatment also had a significant effect in reducing the total symptom score and the duration of infections.
- Medical Journal Publishes Trial Showing Study Results of COLD-fX(R)
The Canadian Medical Association Journal will publish results of double-blind, placebo-controlled study on COLD-fX(R) for prevention and relief of upper respiratory infections; results indicate that the number of upper respiratory infections in each subject was significantly reduced by 25%, recurrent infections were reduced by 56%, and treatment also had a significant effect in reducing the total symptom score and the duration of infections.
- Medical Journal Publishes Trial Showing Study Results of COLD-fX(R)
The Canadian Medical Association Journal will publish results of double-blind, placebo-controlled study on COLD-fX(R) for prevention and relief of upper respiratory infections; results indicate that the number of upper respiratory infections in each subject was significantly reduced by 25%, recurrent infections were reduced by 56%, and treatment also had a significant effect in reducing the total symptom score and the duration of infections.
- Medical Journal Publishes Trial Showing Study Results of COLD-fX(R)
The Canadian Medical Association Journal will publish results of double-blind, placebo-controlled study on COLD-fX(R) for prevention and relief of upper respiratory infections; results indicate that the number of upper respiratory infections in each subject was significantly reduced by 25%, recurrent infections were reduced by 56%, and treatment also had a significant effect in reducing the total symptom score and the duration of infections.
- Annual Bibliography of Significant Advances in Dietary Supplement Research 2004
This sixth issue of the Bibliography includes abstracts of the 25 most noteworthy dietary supplement research papers published in 2004, as judged by an international team of reviewers; This is the first issue of the Bibliography to highlight research on phenolics and flavonoids.
- Annual Bibliography of Significant Advances in Dietary Supplement Research 2004
This sixth issue of the Bibliography includes abstracts of the 25 most noteworthy dietary supplement research papers published in 2004, as judged by an international team of reviewers; This is the first issue of the Bibliography to highlight research on phenolics and flavonoids.
- Annual Bibliography of Significant Advances in Dietary Supplement Research 2004
This sixth issue of the Bibliography includes abstracts of the 25 most noteworthy dietary supplement research papers published in 2004, as judged by an international team of reviewers; This is the first issue of the Bibliography to highlight research on phenolics and flavonoids.
- New Clinical Trial Demonstrates Effectiveness of SierraSil®, Nutraceutical Mineral Complex for Osteoarthritis
Results of double-blind, randomized, placebo-controlled, multi-centered clinical trial, published in the Journal of Inflammation, indicate that SierraSil provided significant symptomatic relief after one week, to patients with osteoarthritis of the knee.
- New Clinical Trial Demonstrates Effectiveness of SierraSil®, Nutraceutical Mineral Complex for Osteoarthritis
Results of double-blind, randomized, placebo-controlled, multi-centered clinical trial, published in the Journal of Inflammation, indicate that SierraSil provided significant symptomatic relief after one week, to patients with osteoarthritis of the knee.
- New Clinical Trial Demonstrates Effectiveness of SierraSil®, Nutraceutical Mineral Complex for Osteoarthritis
Results of double-blind, randomized, placebo-controlled, multi-centered clinical trial, published in the Journal of Inflammation, indicate that SierraSil provided significant symptomatic relief after one week, to patients with osteoarthritis of the knee.
- New Clinical Trial Demonstrates Effectiveness of SierraSil®, Nutraceutical Mineral Complex for Osteoarthritis
Results of double-blind, randomized, placebo-controlled, multi-centered clinical trial, published in the Journal of Inflammation, indicate that SierraSil provided significant symptomatic relief after one week, to patients with osteoarthritis of the knee.
- New Clinical Trial Demonstrates Effectiveness of SierraSil®, Nutraceutical Mineral Complex for Osteoarthritis
Results of double-blind, randomized, placebo-controlled, multi-centered clinical trial, published in the Journal of Inflammation, indicate that SierraSil provided significant symptomatic relief after one week, to patients with osteoarthritis of the knee.
- Study Examines the Safe Consumption Of Soy Isoflavones As Hormone Replacement Therapy
New results, based on studies of an experimental model designed to investigate consumption of soy-derived products as a natural alternative to hormone replacement therapy in post-menopausal breast cancer women, were presented today at the 6th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease; results indicate that consumption of Soyselect® does not stimulate the growth of breast cancer tumors in the experimental model used (xenograft MCF-7).
- Study Examines the Safe Consumption Of Soy Isoflavones As Hormone Replacement Therapy
New results, based on studies of an experimental model designed to investigate consumption of soy-derived products as a natural alternative to hormone replacement therapy in post-menopausal breast cancer women, were presented today at the 6th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease; results indicate that consumption of Soyselect® does not stimulate the growth of breast cancer tumors in the experimental model used (xenograft MCF-7).
- Study Examines the Safe Consumption Of Soy Isoflavones As Hormone Replacement Therapy
New results, based on studies of an experimental model designed to investigate consumption of soy-derived products as a natural alternative to hormone replacement therapy in post-menopausal breast cancer women, were presented today at the 6th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease; results indicate that consumption of Soyselect® does not stimulate the growth of breast cancer tumors in the experimental model used (xenograft MCF-7).
- Study Examines the Safe Consumption Of Soy Isoflavones As Hormone Replacement Therapy
New results, based on studies of an experimental model designed to investigate consumption of soy-derived products as a natural alternative to hormone replacement therapy in post-menopausal breast cancer women, were presented today at the 6th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease; results indicate that consumption of Soyselect® does not stimulate the growth of breast cancer tumors in the experimental model used (xenograft MCF-7).
- Study Examines the Safe Consumption Of Soy Isoflavones As Hormone Replacement Therapy
New results, based on studies of an experimental model designed to investigate consumption of soy-derived products as a natural alternative to hormone replacement therapy in post-menopausal breast cancer women, were presented today at the 6th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease; results indicate that consumption of Soyselect® does not stimulate the growth of breast cancer tumors in the experimental model used (xenograft MCF-7).
- Study Examines Anticancer Effect of Herbal Medicine in Cancer Cells
A new study in cancer cell lines has found that the gamma-linolenic acid (GLA)--a polyunsaturated fatty acid found in several plant oils, affects the expression of the Her-2/neu oncogene, in a different way from the monoclonal antibody approved for treatment of breast cancer patients with high levels of Her-2/neu.
- Study Examines Anticancer Effect of Herbal Medicine in Cancer Cells
A new study in cancer cell lines has found that the gamma-linolenic acid (GLA)--a polyunsaturated fatty acid found in several plant oils, affects the expression of the Her-2/neu oncogene, in a different way from the monoclonal antibody approved for treatment of breast cancer patients with high levels of Her-2/neu.
- Study Examines Anticancer Effect of Herbal Medicine in Cancer Cells
A new study in cancer cell lines has found that the gamma-linolenic acid (GLA)--a polyunsaturated fatty acid found in several plant oils, affects the expression of the Her-2/neu oncogene, in a different way from the monoclonal antibody approved for treatment of breast cancer patients with high levels of Her-2/neu.
- ForsLean Increases Lean Body Mass and Reduces Body Fat Percentages According to Recent Study
12-week randomized, double-blind, placebo-controlled study of 50 obese men and women revealed that subjects receiving ForsLean had a statistically significant increase in lean body mass of 1.78 percent compared to a 0.20 percent decrease in the placebo group.
- ForsLean Increases Lean Body Mass and Reduces Body Fat Percentages According to Recent Study
12-week randomized, double-blind, placebo-controlled study of 50 obese men and women revealed that subjects receiving ForsLean had a statistically significant increase in lean body mass of 1.78 percent compared to a 0.20 percent decrease in the placebo group.
- ForsLean Increases Lean Body Mass and Reduces Body Fat Percentages According to Recent Study
12-week randomized, double-blind, placebo-controlled study of 50 obese men and women revealed that subjects receiving ForsLean had a statistically significant increase in lean body mass of 1.78 percent compared to a 0.20 percent decrease in the placebo group.
- ForsLean Increases Lean Body Mass and Reduces Body Fat Percentages According to Recent Study
12-week randomized, double-blind, placebo-controlled study of 50 obese men and women revealed that subjects receiving ForsLean had a statistically significant increase in lean body mass of 1.78 percent compared to a 0.20 percent decrease in the placebo group.
- Fonterra Expands Research Capability to Australia
Company will estblish a NZ$16 million dairy innovation centre in Melbourne, due to open in April 2007, to focus on consumer dairy products, complementing its main research facilities in Palmerston North.
- Fonterra Expands Research Capability to Australia
Company will estblish a NZ$16 million dairy innovation centre in Melbourne, due to open in April 2007, to focus on consumer dairy products, complementing its main research facilities in Palmerston North.
- NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health
Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis".
- NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health
Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis".
- NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health
Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis".
- NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health
Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis".
- NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health
Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis".
- NIH Study Examines the Efficacy and Safety of Glucosamine and Chondroitin in Promoting Knee Joint Health
Initial findings from GAIT study indicate that "combination glucosamine and chondroitin is effective in treating moderate to severe knee pain due to osteoarthritis".
- NCCAM Statement on Presentation of GAIT Results at ACR Meeting
NCCAM and our NIH study co-sponsor, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, are refraining from comment on the study until the full results are published in the peer-reviewed literature.
- NCCAM Statement on Presentation of GAIT Results at ACR Meeting
NCCAM and our NIH study co-sponsor, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, are refraining from comment on the study until the full results are published in the peer-reviewed literature.
- NIH-Sponsored Trial Shows Supplements Relieve Arthritis Pain
Council for Responsible Nutrition comments on recently released clinical trial results of glucosamine and chondroitin and pain relief from osteoarthritis.
- NIH-Sponsored Trial Shows Supplements Relieve Arthritis Pain
Council for Responsible Nutrition comments on recently released clinical trial results of glucosamine and chondroitin and pain relief from osteoarthritis.
- NIH-Sponsored Trial Shows Supplements Relieve Arthritis Pain
Council for Responsible Nutrition comments on recently released clinical trial results of glucosamine and chondroitin and pain relief from osteoarthritis.
- NIH-Sponsored Trial Shows Supplements Relieve Arthritis Pain
Council for Responsible Nutrition comments on recently released clinical trial results of glucosamine and chondroitin and pain relief from osteoarthritis.
- NIH-Sponsored Trial Shows Supplements Relieve Arthritis Pain
Council for Responsible Nutrition comments on recently released clinical trial results of glucosamine and chondroitin and pain relief from osteoarthritis.
- New Findings Suggest Keratin Ingredient Cynatine FLX Activates Joint Defense Enzymes
Recent laboratory research on rats suggests that the new keratin joint ingredient Cynatine FLX activates two important joint antioxidant defense enzymes (glutathione peroxidase (GSH-PX) and superoxide dismutase (SOD)) and stimulates the regeneration of cells.
- New Findings Suggest Keratin Ingredient Cynatine FLX Activates Joint Defense Enzymes
Recent laboratory research on rats suggests that the new keratin joint ingredient Cynatine FLX activates two important joint antioxidant defense enzymes (glutathione peroxidase (GSH-PX) and superoxide dismutase (SOD)) and stimulates the regeneration of cells.
- New Findings Suggest Keratin Ingredient Cynatine FLX Activates Joint Defense Enzymes
Recent laboratory research on rats suggests that the new keratin joint ingredient Cynatine FLX activates two important joint antioxidant defense enzymes (glutathione peroxidase (GSH-PX) and superoxide dismutase (SOD)) and stimulates the regeneration of cells.
- New Findings Suggest Keratin Ingredient Cynatine FLX Activates Joint Defense Enzymes
Recent laboratory research on rats suggests that the new keratin joint ingredient Cynatine FLX activates two important joint antioxidant defense enzymes (glutathione peroxidase (GSH-PX) and superoxide dismutase (SOD)) and stimulates the regeneration of cells.
- New Findings Suggest Keratin Ingredient Cynatine FLX Activates Joint Defense Enzymes
Recent laboratory research on rats suggests that the new keratin joint ingredient Cynatine FLX activates two important joint antioxidant defense enzymes (glutathione peroxidase (GSH-PX) and superoxide dismutase (SOD)) and stimulates the regeneration of cells.
- Broccoli Sprouts Found to Boost Body's Ability to Eliminate Cancer-Causing Toxins in Human Study
A team from Johns Hopkins University School of Medicine and Bloomberg School of Public Health, in collaboration with scientists at the Qidong Liver Cancer Institute, Jiao Tong University in Shanghai and the University of Minnesota Cancer Center, in a blinded placebo-controlled study published in the November issue of Cancer Epidemiology Biomarkers & Prevention, have observed that broccoli sprouts can help the body detoxify carcinogens, which may reduce the risk of developing liver cancer. The study used Three-day-old broccoli sprouts with known levels of sulforaphane glucosinolate (SGS(TM)) and involved 200 subjects in total
- Broccoli Sprouts Found to Boost Body's Ability to Eliminate Cancer-Causing Toxins in Human Study
A team from Johns Hopkins University School of Medicine and Bloomberg School of Public Health, in collaboration with scientists at the Qidong Liver Cancer Institute, Jiao Tong University in Shanghai and the University of Minnesota Cancer Center, in a blinded placebo-controlled study published in the November issue of Cancer Epidemiology Biomarkers & Prevention, have observed that broccoli sprouts can help the body detoxify carcinogens, which may reduce the risk of developing liver cancer. The study used Three-day-old broccoli sprouts with known levels of sulforaphane glucosinolate (SGS(TM)) and involved 200 subjects in total
- Broccoli Sprouts Found to Boost Body's Ability to Eliminate Cancer-Causing Toxins in Human Study
A team from Johns Hopkins University School of Medicine and Bloomberg School of Public Health, in collaboration with scientists at the Qidong Liver Cancer Institute, Jiao Tong University in Shanghai and the University of Minnesota Cancer Center, in a blinded placebo-controlled study published in the November issue of Cancer Epidemiology Biomarkers & Prevention, have observed that broccoli sprouts can help the body detoxify carcinogens, which may reduce the risk of developing liver cancer. The study used Three-day-old broccoli sprouts with known levels of sulforaphane glucosinolate (SGS(TM)) and involved 200 subjects in total
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
West Chicago, IL - This morning a study by the Lewin Group was released which determined that by taking certain dietary supplements (specifically, lutein with zeaxanthin, and omega 3 fatty acids), senior citizens can lead healthier, more productive and more independent lives. This results in more than $5 billion in savings to the Medicare system over five years in reduced hospitalizations and physician services.
The study stated that visual impairment is one of the top four reasons people loose their independence as they age. It is both common, with 35 percent of individuals aged 75 and older having Age-Related Macular Degeneration (AMD), and costly. The study uses as an example the fact that eighteen percent of all hip fractures among seniors are attributed to age-related vision loss. The decreased independence resulting from loss of vision places a significant financial burden on the person, their family and the entire health care system.
The Lewin Group estimates a $2.5 billion net savings over five years (2006-2010) from a reduction in the relative risk of AMD through daily intake of 6-10 milligrams of lutein with zeaxanthin. In those five years, approximately 98,219 people could avoid the transition to dependence either in the community or a nursing facility that would accompany a vision loss resulting from advanced AMD through lutein with zeaxanthin supplementation.
Lutein has become increasingly popular, and is now included in many multivitamins. Omega 3s, likewise, are gaining in popularity as people add more fish to their diets or supplement with Omega 3 capsules. Zeaxanthin, however, is only beginning to be recognized as an important ingredient by the general population.
Zeaxanthin (pronounced zee-uh-zan’-thin) is a dietary carotenoid found mostly in the macula, the central part of the retina in the eye that is responsible for most fine vision. Zeaxanthin, like lutein, is thought to be a critical nutrient for eye health and can help guard against age-related vision loss. Zeaxanthin and lutein molecules always exist in tandem, but the ratios are what differ.
Chrysantis™, Inc., the maker of the only natural zeaxanthin on the market, is working to build awareness about the importance of zeaxanthin in eye health, which has the potential to positively impact millions of people that either have or are at risk of having AMD.
According to Chrysantis General Manager Manuel Pavon, “Macular degeneration is one of the age-related conditions which people are learning to guard against through supplements. The Lewin study correctly points out that when it comes to the prevention of AMD one should look for products containing both zeaxanthin and lutein. Many zeaxanthin and lutein products have been launched this year, making possible for people to have the best possible protection.”
He goes on to say, “Recent research indicates that zeaxanthin supplementation is particularly important for women; this is being recognized by the NEI which is sponsoring a study called: Carotenoids and Age-Related Eye Disease in Women's Health Study.”
Zeaxanthin, like lutein, is made from Marigold flowers. A typical Marigold flower carotenoid profile is 80 percent lutein and 5 percent zeaxanthin. Chrysantis has a wide range of proprietary zeaxanthin-lutein Marigolds with profiles that range from 75 percent zeaxanthin and 5 percent lutein to 50 percent zeaxanthin and 50 percent lutein. Chrysantis sells its branded extracts under the name EZ Eyes™.
Chrysantis, Inc., a wholly owned subsidiary of Ball Horticultural Company based in West Chicago, IL, is dedicated to developing high-quality plant-based products for dietary supplement manufacturers and the functional foods industry that will enhance human health. Family-owned Ball Horticultural Company has been researching, breeding and selling the highest-quality flower seed varieties for 100 years. The company’s understanding of the compounds that are responsible for flower color (carotenoids, anthocyanins, flavonoids) led to the creation of Chrysantis, which aims to bring those products to market.
For more information, call 630 588-3474 or visit www.Chrysantis.com.
For more information:
Suzanne Shelton 847-676-4337
Suzanne@SheltonGroupPR.com
|